A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

被引：15

作者：

Kumar P.N. ^{[1
]}

Salvato P. ^{[2
]}

LaMarca A. ^{[3
]}

DeJesus E. ^{[4
]}

Patel P. ^{[5
]}

McClernon D. ^{[5
]}

Florance A. ^{[5
]}

Shaefer M.S. ^{[5
]}

机构：

[1] Georgetown University Medical Center, Washington, DC

[2] Diversified Medical Practice, Houston, TX

[3] Therafirst Medical Centers Inc, Ft. Lauderdale, FL

[4] Orlando Immunology Center, Orlando, FL

[5] GlaxoSmithKline, Research Triangle Park, NC

来源：

AIDS Research and Therapy | / 6卷 / 1期

关键词：

Virologic Response; Atazanavir; Virologic Failure; AIDS Clinical Trial Group; Fosamprenavir;

D O I：

10.1186/1742-6405-6-3

中图分类号：

学科分类号：

摘要：

Background: Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co-morbidities, women of child-bearing potential, and intolerability to components of standard first line therapy. This study was conducted to determine if alternate treatment options may meet the needs of both general and special patient populations. The ACTION study was a randomized, open-label, multicenter, 48-week trial that compared the safety and efficacy of a triple nucleoside regimen versus a protease inhibitor plus a dual nucleoside regimen in HIV-1 treatment-naïve subjects. Results 279 HIV-infected subjects with HIV-1 RNA (VL) <5000 but < 200,000 copies/mL (c/mL) and CD4+ count ≥ 100 cells/mm3 were randomized (1:1) to receive abacavir sulfate/lamivudine/zidovudine (ABC/ 3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/ zidovudine (3TC/ZDV) twice-daily. Protocol-defined virologic failure was based on multiple failure criteria. Non-inferiority of ABC/3TC/ZDV to ATV+3TC/ZDV was established with 62% vs. 59% of subjects achieving a VL < 50 c/mL at week 48, [ITT(E), M/S = F, 95% CI: -5.9, 10.4]. Similar results were observed in the 230 (82%) subjects with baseline VL<100,000 c/mL (ABC/3TC/ZDV vs. ATV+3TC/ZDV), 66% vs. 59%; 95% CI: -5.6, 19.5. However, ABC/3TC/ZDV did not meet the non-inferiority criterion compared to ATV+3TC/ZDV in the 48 subjects with baseline VL ≥ 100,000 c/mL, 39% vs. 60%; 95% CI: -49.2, 7.4, respectively. Protocol-defined virologic failure was similar between groups. Conclusion: ABC/3TC/ZDV demonstrated comparable virologic efficacy to ATV+3TC/ZDV in this population over 48 weeks. In those with a baseline VL ≥ 100,000 c/mL, subjects in the ATV+3TC/ZDV showed better virologic efficacy. Both regimens offer benefits in select therapy-naïve subjects. Trial Registration: [Clinical Trials Identifier, NCT00082394]. © 2009 Kumar et al; licensee BioMed Central Ltd.

引用

共 16 条

[1]

Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents

[2]

Staszewski S., Keiser P., Montaner J., Raffi F., Gathe J., Brotas V., Hicks C., Hammer S.M., Cooper D., Johnson M., Tortell S., Cutrell A., Thorborn D., Isaacs R., Hetherington S., Steel H., Spreen W., CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial, JAMA, 285, pp. 1155-1163, (2001)

[3]

Vibhagool A., Capn P., Schechter M., Smaill F., Soto-Ramirez L., Carosi G., Montroni M., Pharo C.E., Jordan J.C., Thomas N.E., Pearce G., Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: Results of a 48-week open-label, equivalence trial (CNA3014), Curr Med Res Opin, 20, pp. 1103-1114, (2004)

[4]

Kumar P.N., Rodriguez-French A., Thompson M.A., Tashima K.T., Averitt D., Wannamaker P.G., Williams V.C., Shaefer M.S., Pakes G.E., Pappa K.A., A prospective, 96-week study of the impact of Trizivir, Combivir/ nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: Effect of sex and ethnicity, HIV Med, 7, pp. 85-98, (2006)

[5]

Gulick R.M., Ribaudo H.J., Shikuma C.M., Lustgarten S., Squires K.E., Meyer III W.A., Acosta E.P., Schackman B.R., Pilcher C.D., Murphy R.L., Maher W.E., Witt M.D., Reichman R.C., Snyder S., Klingman K.L., Kuritzkes D.R., Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection, N Engl J Med, 350, pp. 1850-1861, (2004)

[6]

Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents, pp. 1-139, (2008)

[7]

Malan N., Krantz E., David N., Et al., Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089, 13th Conference on Retroviruses and Opportunistic Infections, (2006)

[8]

Reyataz® (atazanavir sulfate) [Product information], (2007)

[9]

NIAID Division of AIDS Table Forgrading Severity of Adult Adverse Experiences, (1992)

[10]

Hirsch M.S., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., Demeter L.M., Hammer S.M., Johnson V.A., Loveday C., Mellors J.W., Jacobsen D.M., Richman D.D., Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel, Clin Infect Dis, 37, pp. 113-128, (2003)

← 1 2 →